Patrick Vermersch, MD, PhD

Articles by Patrick Vermersch, MD, PhD

BTKi Treatment Paradigm

ByJiwon Oh, MD, PhD,Gavin Giovannoni, MBBCh, PhD, FCP, FRCP, FRCPath,Amit Bar-Or, MD, FRCPC,Krzysztof Selmaj, MD, PhD,Patrick Vermersch, MD, PhD

December 4th 2023

Neurology experts discuss where BTKi’s fit in the multiple sclerosis treatment continuum.

BTKi Treatment: Clinical Measures

ByJiwon Oh, MD, PhD,Gavin Giovannoni, MBBCh, PhD, FCP, FRCP, FRCPath,Amit Bar-Or, MD, FRCPC,Krzysztof Selmaj, MD, PhD,Patrick Vermersch, MD, PhD

December 4th 2023

Experts provide insights about what clinical measures they look for when treating patients with BTKis for multiple sclerosis.

BTKi Effect on Chronic Active Lesions

ByJiwon Oh, MD, PhD,Gavin Giovannoni, MBBCh, PhD, FCP, FRCP, FRCPath,Amit Bar-Or, MD, FRCPC,Krzysztof Selmaj, MD, PhD,Patrick Vermersch, MD, PhD

December 4th 2023

Neurology experts discuss the potential effects of BTKi on chronic active lesions during multiple sclerosis therapies.

BTKi Mechanism of Action

ByJiwon Oh, MD, PhD,Gavin Giovannoni, MBBCh, PhD, FCP, FRCP, FRCPath,Amit Bar-Or, MD, FRCPC, FAAN, FANA,Krzysztof Selmaj, MD, PhD,Patrick Vermersch, MD, PhD

November 27th 2023

Neurology experts discuss the mechanism of action of BTKi’s for the treatment of multiple sclerosis.

BTKi Safety Concerns

ByJiwon Oh, MD, PhD,Gavin Giovannoni, MBBCh, PhD, FCP, FRCP, FRCPath,Amit Bar-Or, MD, FRCPC, FAAN, FANA,Krzysztof Selmaj, MD, PhD,Patrick Vermersch, MD, PhD

November 27th 2023

Experts lead a discussion about potential safety concerns of BTKi’s when treating patients with multiple sclerosis.

Phase II Clinical Trial: Tolebrutinib

ByJiwon Oh, MD, PhD,Gavin Giovannoni, MBBCh, PhD, FCP, FRCP, FRCPath,Amit Bar-Or, MD, FRCPC,Krzysztof Selmaj, MD, PhD,Patrick Vermersch, MD, PhD

November 21st 2023

Jiwon Oh, MD, PhD, FRCPC, provides an overview of phase II results of tolebrutinib for the treatment of multiple sclerosis.

Phase II Clinical Trial: Fenebrutinib

ByJiwon Oh, MD, PhD,Gavin Giovannoni, MBBCh, PhD, FCP, FRCP, FRCPath,Amit Bar-Or, MD, FRCPC,Krzysztof Selmaj, MD, PhD,Patrick Vermersch, MD, PhD

November 13th 2023

Amit Bar-Or, MD, FRCPC, summarizes fenebrutinib phase II results for the treatment of multiple sclerosis.

Phase II Clinical Trial: Evobrutinib

ByJiwon Oh, MD, PhD,Gavin Giovannoni, MBBCh, PhD, FCP, FRCP, FRCPath,Amit Bar-Or, MD, FRCPC,Krzysztof Selmaj, MD, PhD,Patrick Vermersch, MD, PhD

November 13th 2023

Patrick Vermersch, MD, PhD, summarizes phase II clinical trial of evobrutinib for the treatment of multiple sclerosis.

BTK Inhibitor Clinical Development

ByJiwon Oh, MD, PhD,Gavin Giovannoni, MBBCh, PhD, FCP, FRCP, FRCPath,Amit Bar-Or, MD, FRCPC, FAAN, FANA,Krzysztof Selmaj, MD, PhD,Patrick Vermersch, MD, PhD

November 6th 2023

Patrick Vermersch, MD, PhD, and Krzysztof Selmaj, MD, PhD, provide an overview of the BTKi that are currently under investigation for MS, and Gavin Giovannoni, MBBCh, PhD, FCP, FRCP, FRCPath, discusses what in vivo and in vitro preclinical work in models of MS have shown.

BTK Inhibitor Overview

ByJiwon Oh, MD, PhD,Gavin Giovannoni, MBBCh, PhD, FCP, FRCP, FRCPath,Amit Bar-Or, MD, FRCPC, FAAN, FANA,Krzysztof Selmaj, MD, PhD,Patrick Vermersch, MD, PhD

November 6th 2023

Amit Bar-Or, MD, FRCPC, provides an overview of the history of BTKi’s as well as what makes this class of drug a promising target for relapsing and remitting forms of MS.